Human Cytochromes P450 Associated with the Phase 1 Metabolism of Drugs and other Xenobiotics: A Compilation of Substrates and Inhibitors of the CYP1, CYP2 and CYP3 Families

Lewis, David F.V.
October 2003
Current Medicinal Chemistry;Oct2003, Vol. 10 Issue 19, p1955
Academic Journal
This review represents a compilation of typical substrates and inhibitors for human cytochrome P450 (CYP) enzymes that are involved in drug metabolism, specifically those from the CYP1, CYP2 and CYP3 families. Relatively recent literature on substrates and inhibitors has been collected and the relevant Km and Ki values, respectively, are tabulated. Furthermore, physicochemical properties in the form of lipophilicity (log P and log D7.4 values) and acidity / basicity (pKa values) are also tabulated for a significant number of substrates, together with some information on inhibitors, although only key inhibitors have been selected as the main focus is on substrates. The collated information indicates that there are certain commonalities between substrates for the same enzyme, especially with respect to their positions of metabolism and likely interactions with the relevant enzyme active site regions. The compilation therefore assists in establishing substrate structure-activity relationships (SSARs) within human drug-metabolizing P450s.


Related Articles

  • Kidney CYP450 Enzymes: Biological Actions Beyond Drug Metabolism. Zhao, X.; Imig, J.D. // Current Drug Metabolism;Feb2003, Vol. 4 Issue 1, p73 

    Arachidonic acid can be metabolized by cytochrome P450 (CYP450) enzymes to 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids (EETs), their corresponding dihydroxyeicosatrienoic acids (DHETs), and 20-hydroxyeicosatetraenoic acid (20-HETE). These arachidonic acid metabolites are involved in...

  • Prediction of Human Drug Metabolizing Enzyme Induction. Mankowski, Dayna C.; Ekins, Sean // Current Drug Metabolism;Oct2003, Vol. 4 Issue 5, p381 

    New chemical entities are routinely screened in vitro and in vivo for their ability to induce cytochrome P450s (CYP), other drug-metabolizing enzymes and possibly transporters in an attempt to more accurately predict clinical parameters such as drug-drug interactions and clearance in humans....

  • The Effect of Psoralens on Hepatic and Cutaneous Drug Metabolizing Enzymes and Cytochrome P-450. Bickers, David R.; Mukhtar, Hasan; Molica Jr., S. J.; Pathak, Madhu A. // Journal of Investigative Dermatology;Sep82, Vol. 79 Issue 3, p201 

    Psoralens are tricyclic furocoumarins with potent photosensitizing properties in the skin and are now widely used in the treatment of several dermatologic diseases. In this study the effect of 3 different psoralens 8-methoxypsoralen (8-MOP), 4,5',8-trimethylpsoralen (TMP) and isopsoralen on...

  • A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. Kriegl, Jan; Arnhold, Thomas; Beck, Bernd; Fox, Thomas // Journal of Computer-Aided Molecular Design;Mar2005, Vol. 19 Issue 3, p189 

    The cytochrome P450 (CYP) enzyme superfamily plays a major role in the metabolism of commercially available drugs. Inhibition of these enzymes by a drug may result in a plasma level increase of another drug, thus leading to unwanted drug–drug interactions when two or more drugs are...

  • Effect of Some Biologically Interesting Substituted Tetrahydro-1,4- Oxazines on Drug Metabolising Enzymes and on Inflammation. Rekka, E. A.; Kourounakis, A. P.; Avramidis, N.; Kourounakis, P. N. // Current Drug Metabolism;Oct2005, Vol. 6 Issue 5, p481 

    The effect on hepatic drug metabolising enzymes was evaluated for three representative structures (1, 2 and 3) that were selected from a series of substituted oxazine derivatives designed to possess particular pharmacological properties such as analgesic, antioxidant and hypolipidemic activity....

  • Comparison of Enzyme Kinetic Parameters Obtained In Vitro for Reactions Mediated by Human CYP2C Enzymes Including Major CYP2C9 Variants. Rokitta, D.; Fuhr, U. // Current Drug Metabolism;Feb2010, Vol. 11 Issue 2, p153 

    Cytochrome P450 (CYP) 2C enzymes contribute to the metabolism of about 30% of all drugs. Known polymorphisms of the respective enzymes and drug-drug interactions have a major impact on the efficacy and safety of some CYP2C substrate drugs. In vivo -- in vitro correlations including prediction of...

  • Electronic and Structural Aspects of P450-Mediated Drug Metabolism. Lewis, David F. V.; Ito, Yuko; Lake, Brian G. // Drug Metabolism Letters;Apr2009, Vol. 3 Issue 2, p87 

    From a consideration of first principles for enzymes kinetics, we have employed theoretical methods which enable one to analyse the kinetics of cytochrome P450-mediated reactions which have been based on the known physicochemical principles underlying the majority of chemical or enzymatic...

  • Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development. Nettleton, David O.; Einolf, Heidi J. // Current Topics in Medicinal Chemistry;Feb2011, Vol. 11 Issue 4, p382 

    Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs. CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic...

  • Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450. Niwa, Toshiro; Murayama, Norie; Yamazaki, Hiroshi // Current Drug Metabolism;Sep2009, Vol. 10 Issue 7, p700 

    Cytochrome P450s (P450 or CYPs) comprise a superfamily of enzymes that catalyze the oxidation of a wide variety of xenobiotic chemicals including drugs and environmental carcinogens. Recent studies have demonstrated that endogenous chemicals are also oxidized by human P450s which mainly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics